In recent years, multiple reports have shown that BRCA1, BRCA2 and PALB2 genes, which are known as “the core homologous recombination (HR) genes”, present germline mutations in up to 5% of patients with pancreatic cancer. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.